Definitive Carbon-Ion Radiation Therapy for Locally Advanced Sinonasal Malignant Tumors: Subgroup Analysis of a Multicenter Study by the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS)
Definitive Carbon-Ion Radiation Therapy for Locally Advanced Sinonasal Malignant Tumors: Subgroup Analysis of a Multicenter Study by the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS)
复制标题
DOI：
10.1016/j.ijrobp.2018.05.074
复制
发表时间：
2018-10-01
影响因子：
7
通讯作者：
Kamada, Tadashi
中科院分区：
文献类型：
--
作者：
Koto, Masashi;Demizu, Yusuke;Kamada, Tadashi
目的：通过一项多中心的回顾性研究(J-CROS 1402 HN)，评价碳离子放射治疗(C-ion RT)治疗局部晚期鼻鼻恶性肿瘤的安全性和有效性。方法：收集2003年11月至2014年12月在日本4家医疗机构接受C-ion RT治疗的N0-1M0期鼻腔恶性肿瘤患者的临床资料。在458名患者中，393名患者为初治肿瘤，65名患者为复发性肿瘤。肿瘤位于鼻腔263例，上颌窦109例，筛窦71例，其他部位15例。病理类型：粘膜黑色素瘤221例(48%)，腺样囊性癌122例(27%)，鳞癌31例(7%)，嗅神经母细胞瘤30例(7%)，腺癌21例(5%)，其他类型33例(7%)。在458名患者中，300名(66%)患有T4肿瘤。结果：所有患者的中位随访期为25.2月(范围为1.4-132.3个月)。2年总生存率为79.6%，局部控制率为84.1%。根据组织学分析，黏膜黑色素瘤、腺样囊性癌、鳞癌、嗅神经母细胞瘤和腺癌的2年总生存率分别为68.0%、96.8%、70.0%、96.7%和89.7%。在晚期毒性方面，17%的患者出现3级和4级毒性，其中视力损害最常见。结论：我们的多中心研究结果表明，C-ion RT在局部晚期鼻腔恶性肿瘤患者中可以提供良好的临床疗效和可接受的晚期毒性。(C)2018年提交人(S)。由爱思唯尔公司出版。
Purpose: To evaluate the safety and efficacy of carbon-ion radiation therapy (C-ion RT) for locally advanced sinonasal malignant tumors in a multicenter retrospective study (J-CROS 1402 HN).Methods and Materials: Clinical data were collected for patients who had sinonasal malignant tumors of stage N0-1M0 and received C-ion RT at 4 institutions in Japan between November 2003 and December 2014. Of the 458 patients, 393 had naive tumors and 65 had recurrent tumors. The tumors were located in the nasal cavity (n = 263), maxillary sinus (n = 109), ethmoid sinus (n = 71), and other locations (n = 15). The histologic types were mucosal melanoma (n = 221, 48%), adenoid cystic carcinoma (n = 122, 27%), squamous cell carcinoma (n = 31, 7%), olfactory neuroblastoma (n = 30, 7%), adenocarcinoma (n = 21, 5%), and other types (n = 33, 7%). Of the 458 patients, 300 (66%) had T4 tumors. All patients received definitive C-ion RT.Results: The median follow-up period was 25.2 months for all patients (range, 1.4-132.3 months). The 2-year overall survival and local control rates were 79.6% and 84.1%, respectively. As analyzed according to histology, the 2-year overall survival rate was 68.0% for mucosal melanoma, 96.8% for adenoid cystic carcinoma, 70.0% for squamous cell carcinoma, 96.7% for olfactory neuroblastoma, and 89.7% for adenocarcinoma. Regarding late toxicities, 17% of patients developed grade 3 and 4 toxicities, of which visual impairment was the most common.Conclusion: The results of our multicenter study have demonstrated that C-ion RT can provide excellent clinical outcomes with acceptable late toxicities in patients who have locally advanced sinonasal malignant tumors. (C) 2018 The Author(s). Published by Elsevier Inc.